摘要
目的探讨在原发性肝癌临床诊断中,血清AFP和PIVKA-Ⅱ检测以及肝癌风险评估指数(ASAP)效果分析。方法选取2022年1—6月在本院治疗的由病毒性肝炎引起的原发性肝癌患者和非肝癌患者共454例作为研究对象。其中非肝癌患者设为对照组(n=322),原发性肝癌患者设为实验组(n=132)。给予两组患者实施血清AFP检测和血清PIVKA-Ⅱ检测,并通过肝癌风险评估模型计算出ASAP的值,最后比较两组患者检测结果对原发性肝癌的诊断价值。结果通过对比不同血清检查后,患者的临床诊断价值,数据显示:在原发性肝癌诊断方面,血清异常凝血酶原检测准确性优于血清AFP检测,而在血清AFP检测基础上给予血清PIVKA-Ⅱ检测,可明显提高肝癌的临床诊断,肝癌风险评估指数ASAP可有效预测由病毒性肝炎导致的原发性肝癌的发生。结论在原发性肝癌患者的诊断方面,采用血清PIVKA-Ⅱ和AFP联合检测以及ASAP指数可有助于肝癌临床诊断风险评估,临床效果显著,值得推广应用。
Objective To explore and analyze effect of serum AFP and PIVKA-Ⅱ detection and liver cancer risk assessment index(ASAP)in clinical diagnosis of primary liver cancer.Methods The paper chose 454 patients with primary liver cancer caused by viral hepatitis and non liver cancer in our hospital from January to June 2022 as research subjects.Non liver cancer patients were included in control group(n=322),while primary liver cancer patients in experimental group(n=132),serum AFP and serum PIVKA-Ⅱ was tested,ASAP value was calculated with liver cancer risk assessment model.Finally,diagnostic value of test results for primary liver cancer was compared between two groups.Results Comparing clinical diagnostic value of different serum tests,accuracy of serum abnormal prothrombin detection was better than serum AFP detection in diagnosis of primary liver cancer.Serum PIVKA-Ⅱ detection can significantly improve clinical diagnosis of liver cancer on the basis of serum AFP detection,liver cancer risk assessment index ASAP can predict incidence of primary liver cancer caused by viral hepatitis effectively.Conclusion Combined detection of serum PIVKA-Ⅱ and AFP,and ASAP index can evaluate liver cancer risks in clinical diagnosis with significant clinical effect,which is worthy of promotion and application.
作者
许益国
杜洽军
高山
王翔雲
卞莹莹
XU YiGUO;DU Qinjun;GAO Shan;WANG Xiangyun;BIAN Yingying(Qingyang Traditional Chinese Medicine Hospital,Lanzhou,Gansu 745000;Laboratory Medicine Center,Lanzhou University the Second Hospital,Lanzhou,Gansu 730030)
出处
《智慧健康》
2023年第27期64-67,76,共5页
Smart Healthcare
